Yasuhiro Oki

13.2k total citations · 1 hit paper
207 papers, 6.3k citations indexed

About

Yasuhiro Oki is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Yasuhiro Oki has authored 207 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Pathology and Forensic Medicine, 81 papers in Oncology and 56 papers in Genetics. Recurrent topics in Yasuhiro Oki's work include Lymphoma Diagnosis and Treatment (145 papers), Chronic Lymphocytic Leukemia Research (50 papers) and Viral-associated cancers and disorders (49 papers). Yasuhiro Oki is often cited by papers focused on Lymphoma Diagnosis and Treatment (145 papers), Chronic Lymphocytic Leukemia Research (50 papers) and Viral-associated cancers and disorders (49 papers). Yasuhiro Oki collaborates with scholars based in United States, Japan and Australia. Yasuhiro Oki's co-authors include Jean‐Pierre J. Issa, Anas Younes, Hagop M. Kantarjian, Jaroslav Jelı́nek, Michelle A. Fanale, Sattva S. Neelapu, Luis Fayad, Xuelin Huang, Carlos E. Bueso‐Ramos and Steven M. Horwitz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Yasuhiro Oki

198 papers receiving 6.2k citations

Hit Papers

Results of a randomized s... 2006 2026 2012 2019 2006 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    2006 515 citations Yasuhiro Oki, Jean‐Pierre J. Issa et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Yasuhiro Oki 3.1k 2.3k 2.2k 1.7k 1.3k 207 6.3k
Lisa M. Rimsza 3.5k 1.1× 2.6k 1.1× 1.4k 0.6× 1.6k 0.9× 1.2k 0.9× 199 6.2k
Christian Bastard 3.1k 1.0× 2.3k 1.0× 2.5k 1.1× 2.0k 1.2× 1.9k 1.5× 152 6.4k
Masao Seto 3.3k 1.1× 2.6k 1.1× 3.6k 1.6× 1.2k 0.7× 864 0.7× 239 8.5k
Nathan Fowler 3.6k 1.2× 2.9k 1.2× 1.2k 0.5× 2.5k 1.4× 607 0.5× 267 5.8k
Christian Steidl 3.3k 1.0× 2.5k 1.1× 2.2k 1.0× 1.5k 0.9× 1.1k 0.9× 184 6.5k
Ivana N. Micallef 3.3k 1.1× 3.2k 1.4× 1.3k 0.6× 1.7k 1.0× 2.9k 2.3× 256 7.4k
Vincent Ribrag 3.6k 1.1× 4.6k 2.0× 2.0k 0.9× 1.7k 1.0× 962 0.7× 309 7.9k
Francesc Bosch 5.6k 1.8× 3.4k 1.5× 2.0k 0.9× 4.3k 2.5× 1.2k 0.9× 243 8.7k
Leonhard Müllauer 1.3k 0.4× 1.3k 0.6× 1.8k 0.8× 1.0k 0.6× 829 0.6× 198 5.3k
Eva Kimby 4.9k 1.6× 2.8k 1.2× 826 0.4× 4.0k 2.3× 1.1k 0.9× 203 7.7k

Countries citing papers authored by Yasuhiro Oki

Since Specialization
Citations

This map shows the geographic impact of Yasuhiro Oki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuhiro Oki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuhiro Oki more than expected).

Fields of papers citing papers by Yasuhiro Oki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasuhiro Oki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuhiro Oki. The network helps show where Yasuhiro Oki may publish in the future.

Co-authorship network of co-authors of Yasuhiro Oki

This figure shows the co-authorship network connecting the top 25 collaborators of Yasuhiro Oki. A scholar is included among the top collaborators of Yasuhiro Oki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasuhiro Oki. Yasuhiro Oki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oki, Yasuhiro, et al.. (2024). On Tamagawa numbers of CM tori. Algebra & Number Theory. 18(3). 583–629.
2.
3.
Iyer, Swaminathan P., Lei Feng, Jie Xu, et al.. (2023). TCL-275 Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients With Relapsed or Refractory T-Cell Lymphoma (TCL) With Survival Analysis. Clinical Lymphoma Myeloma & Leukemia. 23. S468–S469. 3 indexed citations
4.
Huen, Auris, Bradley M. Haverkos, Jasmine M. Zain, et al.. (2020). Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers. 12(8). 2293–2293. 55 indexed citations
5.
An, Yi, Wen Jiang, T.Y. Andraos, et al.. (2018). Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiotherapy and Oncology. 131. 88–92. 8 indexed citations
6.
Flinn, Ian W., Susan O’Brien, Brad S. Kahl, et al.. (2017). Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. 131(8). 877–887. 183 indexed citations
7.
Horwitz, Steven M., Raphael Koch, Pierluigi Porcu, et al.. (2017). Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 131(8). 888–898. 204 indexed citations
8.
Nastoupil, Loretta J., Jason R. Westin, Nathan Fowler, et al.. (2017). High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study. Blood. 130. 414–414. 14 indexed citations
9.
10.
Chihara, Dai, Nathan Fowler, Yasuhiro Oki, et al.. (2017). Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types. Blood. 130. 4137–4137. 1 indexed citations
11.
Becnel, Melody, Loretta J. Nastoupil, R. Eric Davis, et al.. (2017). Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial. Blood. 130. 4040–4040. 1 indexed citations
12.
Milgrom, Sarah A., Grace L. Smith, Chelsea C. Pinnix, et al.. (2016). Prognostic Significance of the Postchemotherapy Positron Emission Tomography (PET)/Computed Tomography in Early-Stage Hodgkin Lymphoma: Can PET-Positive Patients Be Cured With Radiation Alone?. International Journal of Radiation Oncology*Biology*Physics. 96(2). S167–S167. 1 indexed citations
13.
Yehia, Zeinab Abou, G. Mikhaeel, Grace L. Smith, et al.. (2016). Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. International Journal of Radiation Oncology*Biology*Physics. 96(5). 951–958. 9 indexed citations
14.
Oki, Yasuhiro, Michelle A. Fanale, Jorge Romaguera, et al.. (2015). Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology. 171(4). 463–470. 68 indexed citations
15.
Strati, Paolo, Yasuhiro Oki, Luis Fayad, et al.. (2014). A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas. Blood. 130(21). 4074–4074. 19 indexed citations
16.
Chihara, Dai & Yasuhiro Oki. (2014). Brentuximab vedotin for treatment of systemic T-cell lymphoma. Expert Opinion on Biological Therapy. 14(10). 1519–1526. 2 indexed citations
17.
UDA, Takaaki, et al.. (2013). LARGE-SCALE BEACH CHANGES CAUSED BY INTERMITTENT SAND TRANSPORT AROUND A ROCKY POINT. Journal of Japan Society of Civil Engineers Ser B3 (Ocean Engineering). 69(2). I_802–I_807. 1 indexed citations
18.
Sakai, Kazuya, et al.. (2011). FIELD EXPERIMENT OF CONTROLLING LONGSHORE SAND TRANSPORT USING STONE GROIN IN SANBYAKKEN REGION IN NAKATSU TIDAL FLAT. Journal of Japan Society of Civil Engineers Ser B3 (Ocean Engineering). 67(2). I_1075–I_1080.
19.
Wang, Michael, Yasuhiro Oki, Barbara Pro, et al.. (2009). Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology. 27(31). 5213–5218. 66 indexed citations
20.
Shu, Jingmin, Jaroslav Jelı́nek, Hao Chang, et al.. (2006). Silencing of Bidirectional Promoters by DNA Methylation in Tumorigenesis. Cancer Research. 66(10). 5077–5084. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa M. Rimsza Breakdown of academic impact, for papers by Christian Bastard Breakdown of academic impact, for papers by Masao Seto Breakdown of academic impact, for papers by Nathan Fowler Breakdown of academic impact, for papers by Christian Steidl Breakdown of academic impact, for papers by Ivana N. Micallef Breakdown of academic impact, for papers by Vincent Ribrag Breakdown of academic impact, for papers by Francesc Bosch Breakdown of academic impact, for papers by Leonhard Müllauer Breakdown of academic impact, for papers by Eva Kimby
Rankless by CCL
2026